Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of COPD (at any position) before or on the index date
* 1 dispensation of BGF on or following the launch date of BGF in Japan
Patients must have evidence of at least one qualifying COPD exacerbation event, which qualify the initiation of triple therapy. The exacerbation event must occur within the 12-month period preceding BGF initiation and on or after BGF launch in Japan (i.e., 04 September 2019). The earliest qualifying COPD exacerbation event will be set as the index date.
* 12 months of continuous health plan enrollment preceding the qualifying COPD exacerbation date
* 1 day of continuous enrollment following the qualifying COPD exacerbation date
Age ≥ 40 years on the qualifying COPD exacerbation date
You may not be if
Presence of ≥ 2 records of respiratory cancer diagnoses occurring at least 1 month apart during the 12-month baseline period preceding the qualifying COPD exacerbation or during the follow-up period
Presence of ≥ 1 dispensation of SITT during the 12-month baseline period preceding the index date through BGF initiation
Patients who only have 1 moderate COPD exacerbation in 12-months period prior to BGF initiation with no dispensation of long-acting inhaled COPD maintenance treatment during the 12-months baseline period preceding the qualifying COPD exacerbation.
Clareo Health | EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
